ランキング価格はじめての方へ
  1. 米国企業
  2. Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.NVCT

時価総額
$1.1億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2022年
12月31日		2023年
12月31日
Net loss-19-22
Cost of share-based payments25
Decrease/(increase) in other current assets0-0
Increase in accounts payable and accrued liabilities4-
(Decrease)/increase in accounts payable--0
Net cash used in operating activities-14-16
(Decrease)/increase in accrued liabilities--0
Increase in accrued compensation and benefits-1
Net cash used in operating activities-14-16
Private Placement-1
Proceeds from Issuance of Common Stock-5
Private Placement-1
Proceeds from Issuance of Common Stock-5
Initial Public Offering3-
Private Placement2-
Issuance costs related to At-the-market offering-0
Proceeds from Issuance Initial Public Offering16-
Initial Public Offering3-
Private Placement2-
Issuance costs related to At-the-market offering-0
Issuance costs related to initial public offering-0
Proceeds from Issuance of Private Placement16-
Net cash provided by financing activities2815
Proceeds from Warrant Exercises-11
Issuance costs related to the exercise of warrants, and preferred investment option-0
Issuance costs related to private placement-1
Net cash provided by financing activities2815
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS14-1
Private Placement-1
Proceeds from Issuance of Common Stock-5
Private Placement-1
Proceeds from Issuance of Common Stock-5
Initial Public Offering3-
Private Placement2-
Issuance costs related to At-the-market offering-0
Proceeds from Issuance Initial Public Offering16-
Initial Public Offering3-
Private Placement2-
Issuance costs related to At-the-market offering-0
Issuance costs related to initial public offering-0
Proceeds from Issuance of Private Placement16-
Net cash provided by financing activities2815
Proceeds from Warrant Exercises-11
Issuance costs related to the exercise of warrants, and preferred investment option-0
Issuance costs related to private placement-1
Net cash provided by financing activities2815
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS14-1
Unpaid Deferred Offering Costs0-
Unpaid Deferred Offering Costs0-